

Award Number: W81XWH-16-1-0189

TITLE: Compensatory Immune Suppression Following PD-1/PD-L1 Checkpoint Blockade in Ovarian Cancer

PRINCIPAL INVESTIGATOR: Keith L. Knutson, PhD

CONTRACTING ORGANIZATION: Mayo Clinic Jacksonville
Jacksonville, FL 32224-1865

REPORT DATE: SEPT 2017

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE*Form Approved*
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE

SEPT 2017

2. REPORT TYPE

Annual

3. DATES COVERED

1SEPT2016-31AUG2017

4. TITLE AND SUBTITLE**Compensatory Immune Suppression Following PD-1/PD-L1 Checkpoint Blockade in Ovarian Cancer****5a. CONTRACT NUMBER**

W81XWH-16-1-0189

5b. GRANT NUMBER

W81XWH-16-1-0189

5c. PROGRAM ELEMENT NUMBER**5d. PROJECT NUMBER****5e. TASK NUMBER****5f. WORK UNIT NUMBER****6. AUTHOR(S)**

Keith L Knutson, PhD

E-Mail: knutson.keith@mayo.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Mayo Clinic Jacksonville

Jacksonville, FL 32224-1865

8. PERFORMING ORGANIZATION REPORT NUMBER**9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSOR/MONITOR'S ACRONYM(S)**

11. NUMBER(S) 28

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

Ovarian cancer (OC) is highly immunogenic and generally speaking, higher lymphocytic infiltration is associated with better outcomes. Despite the presence of anti-tumor immune effectors, however, OCs overcome the immunologic onslaught by complex immune suppression strategies involving infiltration by a variety of specialized lymphoid or myeloid derived suppressor or regulatory cells and/or the direct production and release of factors by the tumor into the tumor microenvironment. PD-1 and its ligands PD-L1 and PD-L2 constitute an important immune regulatory (i.e. checkpoint) pathway which suppresses or impairs effective T, B, and myeloid cell responses both in the initiation and effector phases of the immune response. This regulatory axis is widely thought to be important preventing autoimmunity during traditional immune responses, such as against infectious agents. Tumor regressions in response to PD-1/PD-L1 blockade constitute a minor fraction of the objective responses (which include disease stabilizations and minor regressions) suggesting that there are biologic subsets of tumors that are more amenable to checkpoint blockade or, alternatively, tumors rapidly upregulate compensatory immune suppression mechanisms, following exposure to checkpoint blockade, that prevent their destruction.

15. SUBJECT TERMS

ovarian cancer, ID8/ ID8-F3 tumor, PD-1+ dendritic cells, IL-10 blockade, PD-1 blockade, combination therapy, animal model + ovarian cancer, CD57BL/6 mice + ovarian cancer, intraperitoneal, PD-1 + IL-10, tumor microenvironment and cancer stem cells

16. SECURITY CLASSIFICATION OF:

17. LIMITATION OF ABSTRACT

18. NUMBER OF PAGES

19a. NAME OF RESPONSIBLE PERSON
USAMRMC

a. REPORT

U

b. ABSTRACT

U

c. THIS PAGE
U

UU

28

19b. TELEPHONE NUMBER
(include area code)

Table of Contents

	<u>Page</u>
Introduction_____	5
Body_____	6
Key Research Accomplishments_____	26
Reportable Outcomes_____	26
Conclusion_____	26
References_____	27-28

Introduction: Ovarian cancer (OC) is highly immunogenic and generally speaking, higher lymphocytic infiltration is associated with better outcomes. For example, Zhang showed that higher CD3+ T cell infiltration into OC was associated with markedly improved survival [1]. The proposed project will help us understand the cell components of ovarian tumors and their environment, which may prevent currently available therapies from generating an optimal response and may help us to understand why current ovarian cancer therapies sometimes fail. The proposed work will allow us to identify new targets for therapies and improve on existing therapies. Identification of new or improved therapies in an ovarian cancer animal model is a necessary step before these treatments can be tested in a clinical setting. Improved therapies for patients with ovarian cancer will result in reduction of tumors and longer patient survival time. Immune responses generated by the different vaccination strategies targeting tumors are usually suppressed by variety of inhibitory axes that exist in tumors. Recent research suggests that PD-1/PD-L1 axis is the major inhibitory axis in tumor environment including ovarian tumor environments that can blunt the immune responses generated by cancer vaccines. T cells, which are major effector cells that can kill tumors, are known to express PD-1 molecules, and it has been shown that effector functions are impaired by this PD-1/PD-L1 axis [2]. Previously our laboratory has identified a population of ovarian tumor (mouse and human)-associated dendritic cells (which are antigen presenting cells) that express PD-1, and we observed that these cells mediate the suppression of effector T cells [15]. Our laboratory has also recently shown in murine models that PD-1 blockade can suppress and regress tumors in the peritoneal cavity. However, it is possible that, following exposure to checkpoint (e.g., PD-1) blockade, tumors rapidly upregulate compensatory immune suppression mechanisms that prevent their destruction. This hypothesis is the underlying concept developed in the current studies, specifically focusing on PD-1/PD-L1 blockade. Preliminary studies in immunocompetent mouse models of ovarian cancer have provided compelling evidence that alternate immune suppressive pathways are activated during checkpoint blockade with anti-PD-1 including increased levels of regulatory cytokines such as IL-10, up-regulation of PD-L1 on tumor-infiltrating myeloid cells and increased infiltration of immune suppressive cells, in particular, myeloid-derived suppressor cells. Specific objectives of the proposed work include: identification of cellular and immune mediators of resistance to checkpoint (PD-1) blockade, to determine if combination therapy with IL-10 blockade improves T cell immunity and tumor rejection, and to determine if immunization with multi-antigen vaccines prior to PD-1/checkpoint blockade will enhance anti-tumor immunity and improve survival.

PD-1/B7-H1 axis: PD-1 is an inhibitory receptor that is expressed on the surface of many immune cells types such as T cells, B cells, monocytes, NK cells, and dendritic cells. It has two known ligands PD-L1 (B7-H1) and B7-DC. Ligation of PD-1 by its ligands results in inhibitory responses that blunt the immune responses. In the tumor microenvironment, there is preferential induction of PD-1 as well as PD-L1 on immune cells. Hence, upon ligation of this receptor with its ligand PD-L1, a cascade of suppressive pathways emanate downstream of the receptor that inhibit the immune cell responses. This PD-1 receptor ligation to its ligand B7-H1 and the ensuing signaling cascade is termed as PD-1/PD-L1 axis

Progress report

Specific Aim 1: Identify cellular and immune mediators of resistance to checkpoint blockade

The hypothesis is that single agent checkpoint blockade (anti-PD-1) will result in up-regulation of immune suppression, leading to treatment failure. Murine models of OC will be used using a murine equivalent of the human antibodies available to patients.

Aim 1 Experiment 1: Examine changes in the tumor microenvironment following checkpoint (PD-1) blockade

In preliminary studies (unpublished), we have tested the hypothesis that there are potential compensatory mechanisms activated in response to checkpoint blockade. Dendritic cells (DCs), along with macrophages, are the major myeloid-derived constituents of the tumor microenvironment. In our published studies, we observed that PD-1 was highly expressed on tumor-associated DCs, thus potentially making DCs an important target for PD-1 checkpoint blockade strategies [15]. In this experiment, we have tested the hypothesis that checkpoint blockade results in a compensatory boost in myeloid and lymphoid derived immune suppressive cells which in turn neutralize the capabilities of the increase anti-tumor adaptive immune cells. Immune cells were purified and will be characterized by flow cytometry and multiplexed cytokine analysis, looking for evidence of increased infiltration immune regulatory cell phenotypes. Control and treated mice will be euthanized for collection of tumors at moribund. Tumors will be investigated for changes in the subsets of infiltrating immune suppressive cells. The weight of the greater omentum was be used to measure total tumor burden.

Subtask 1.1: To determine the aggressiveness of P53 mutant cell line against its parental cell type

The first aim is to identify a cell line that has more aggressive properties than the conventional ID8 cell lines that is widely used for ovarian cancer models. We received ID8-F3, a p53 knockout model of ID8 cells from the University of Glasgow. We compared the survival curves of ID8 and ID8-F3 at two different cell numbers and as expected the higher mortality rate was seen in the group that was injected with more cancer cells and we also observed that (Fig.1) the ID8-F3 models have increased aggressiveness compared to conventional ID8 cells in syngeneic mice.




Figure 1 ID8/ID8-F3 Survival comparison: The above survival curve indicates the aggressiveness of ID8-F3 over ID8 cells when mice were injected with these cell lines in different cell numbers. In both cases, ID8-F3 has higher morbidity rates than its parental cell line ID8.

Reportable Outcomes Subtask 1.1:

ID8-F3 cell line was more aggressive than conventional ID8 model. Using CRISPR/Cas9 gene editing [3], generated subline of ID8 bearing loss-of-function deletions in Trp53 demonstrated that these alter tumor growth in the peritoneal cavity. However, we believe that a transplantable model, based on a single genetic background (C57BL/6), which recapitulates disseminated peritoneal disease with ascites and in which multiple genotypes can potentially be rapidly investigated in parallel, is an important adjunct to transgenic models.

Subtask 1.2: Designing the flow panel to look at different immune subsets

In the present experiment, we designed flow panels to test the hypothesis that checkpoint blockade results in a compensatory boost in myeloid and lymphoid derived immune suppressive cells which in turn neutralize the capabilities of the increase antitumor adaptive immune cells. Despite the presence of anti-tumor immune effectors, however, OCs overcome the immunologic onslaught by complex immune suppression strategies involving infiltration by a variety of specialized lymphoid or myeloid derived suppressor or regulatory cells and/or the direct production and release of factors by the tumor into the tumor microenvironment. T regulatory cells (Tregs) are a heterogeneous T cell subpopulation that produce immune-suppressive soluble mediators (such as TGF- β and IL-10) and use cell contact-dependent mechanisms to halt tumor rejecting immune responses. Myeloid cells appear to constitute the vast majority of OC-infiltrating immune suppressive cells. Dendritic cells (DCs) are in high abundance in OC

and they are often immature and immune suppressive. OCs, despite producing danger signals, are generally ineffective in inducing DC maturation, activation and trafficking to lymph nodes which is thought to be due to tumor-induced alterations in DC differentiation thus reducing the number of functional cells available for effective T cell activation and survival in the tumor microenvironment. Myeloid-derived suppressor cells (MDSCs) and macrophages are also recruited into OC, which blocks local immune activation, and induce tumor-promoting chronic inflammation, often using mechanisms similar to that of DCs [4, 5]. Macrophage migration inhibitory factor inhibits the antitumor immune response against OC cells by down regulating NKG2D receptor in NK cells [6]. OCs also express PD-L1 and can directly suppress PD-1+ T cells [7]. Immune cells were purified and characterized by flow cytometry and multiplexed cytokine analysis, looking for evidence of increased infiltration immune regulatory cell phenotypes including macrophages, MDSCs (Gr-1^{lo}CD11b⁺ or Gr-1^{hi}CD11b⁺), immature DCs (CD11b⁺CD11c⁺PD-1⁺), mature DCs (CD11b⁺CD11c⁺Class II^{hi}PD-1⁻) and Tregs (CD4⁺Foxp3⁺). Results are compared with effectors such as activated T cells, B cell, and natural killer cells looking at relative proportions.

General leukocyte gating strategy

- For gating CD45+ cells (leukocytes) in every panel




Figure 2 General gating strategy: All the flow panels were optimized using naïve spleen cells to understand the baseline of different immune subsets in mice. The above figure describes the scatter of all immune subsets in the spleen which is then gated for single cells from which only live cells are accounted for further analysis. CD45+ cells that are gated are a subset of the live cells. Further analyses were done within CD45+ live cells.

T cell activation gating strategy

- For gating CD4+, CD8+, $\gamma\delta$ T cells and expression of activation marker CD69

Within CD45+




Figure 3 T cell activation panel: This figure shows the different T cell subsets within the leukocyte gating (CD45+). T cell receptors which are represented by the CD3 markers are used to identify T cells. Within T cell receptor there are two different subtypes namely $\alpha\beta$ - TCR and $\gamma\delta$ -TCR. More than 80% of the T cells are of $\alpha\beta$ subtypes (Fig. not shown). Earlier studies (not shown here) suggested $\gamma\delta$ -TCR represents immune suppressive phenotype. Moreover the T cells are further classified based on functions namely- T effector (CD8) and T helper (CD4). Both cells were examined for their baseline activation status.

T cell regulation gating strategy

- For gating T_{reg} cells (CD4+CD25+FoxP3+)

Within CD45+




Figure 4 T cell regulation panel: This figure represent a subset of CD4 T helper cells also known as T regulatory cells. These are represented by CD4+CD25+FoxP3+ cells. In the above figure there is an undetectable amount of Treg cells. This is because of the fact that Tregs cells are <2% of the whole T cell population in naïve mice.

Macrophages/MDSC/NK cell gating strategy

- For gating Macrophages (F4/80+CD161-), MDSCs (CD11b+Gr-1+CD161+), Natural Killer cells




Figure 5 Macrophage/ Myeloid derived suppressor cells (MDSCs) panel: This panel represents 3 different immune subsets called macrophages (F4/80+), NK cells (CD161+), MDSCs (GR-1+CD11b+CD161-). Macrophages play a significant part in immunity and immune responses. They assume a defensive role exhibited by their ability to carry on phagocytosis of parasites and microbes. They regulate lymphocyte activation and proliferation and they are essential in the activation process of T- and B-lymphocytes by antigens and allogenic cells. NK cells are cytotoxic cells that play a major role in the host-rejection of both tumors and virally infected cells and are activated in response to interferons or macrophage-derived cytokines. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors, immature granulocytes, macrophages, and dendritic cells at different stages of differentiation. These cells are of great interest because they have the capacity to suppress both the cytotoxic activities of natural killer (NK) and NKT cells, and the adaptive immune response mediated by CD4⁺ and CD8⁺ T cells.

Dendritic Cell/B cell gating strategy

- For gating B cells (CD19+CD161-) and dendritic cells (CD11c+CD161-) and expression of PDL1, MHC Class II, and activation markers CD80 and CD86




Figure 6 DC/ B cell panel: Dendritic cells and B cells are considered as antigen presenting cells (APCs). This panel has multiple co-stimulatory markers that are used to define these two markers. The above figure shows the different co-stimulatory molecules expressed on the surface of DC cells (CD11c+). The B cells (CD19+) have the same co-stimulatory signature (not shown in the above panel).


Reportable Outcomes Subtask 1.2:

Optimization of panels associated with different immune subsets has been validated and these panels will be used for further analysis of various experiments proposed in this grant.

Subtask 1.3: To assess the survival and tumor burden of mice treated with control and anti-PD1 antibody

In preliminary studies (unpublished), we have tested the hypothesis that there are potential compensatory mechanisms activated in response to checkpoint blockade. Dendritic cells (DCs), along with macrophages, are the major myeloid-derived constituents of the tumor microenvironment. In our published studies, we observed that PD-1 was highly expressed on tumor-associated DCs, thus potentially making DCs an important target for PD-1 checkpoint blockade strategies.

A. Body Weights



B. Tumor Burden




Figure 8 Tumor burden and weight assessment: (A) There was no significant change seen in the body mass of tumor bearing mice (n=5) treated with either isotype or anti-PD1 antibody. (B) Both peritoneum and omentum in the treated groups showed no significant change. However, when tumor was measured in the treated mice a significant difference in the anti-PD1 group compared to isotype was observed.

Reportable Outcomes Subtask Aim 1.3:

In this experiment, we have tested the tumor burden in the isotype and anti-PD1 treated mice. There was a significant difference in tumor weight between the groups in the omentum and not in the peritoneum. This result is in accordance with the previous data published from our lab suggesting that the tumor burden is more in the omentum than the peritoneum. We will further assess the body weights from different treatment groups by using scheduled end point study and evaluate different immune subsets and cytokines that are elevated in the different groups processed from ascites and blood.

Aim 1 Experiment 2: Determine immune regulatory signatures of tumor-infiltrating immune suppressive cells resulting from checkpoint blockade. We will also examine functionality of tumor-infiltrating cells

The experiments evaluate only the levels of immune regulatory cells. However, there may be changes in the functions of the infiltrating cells rendering them more suppressive. For example, we have previously isolated tumor-infiltrating DCs from ovarian tumors, treated them *ex vivo* with anti-PD-1 antibody and have evaluated expression of PD-L1, the major mediator of suppression of T cell immunity in the microenvironment. We found that PD-1 blockade results in doubling of the PD-L1 expression which is associated with increased suppressive function. The goal of this experiment is to test the hypothesis that PD-1 blockade results in functional and phenotypic modifications.

Reportable Outcomes Aim 1 Experiment 2:

This experiment is ongoing and we are in the process of evaluating cytokine using cytokine array blot and immune cells by flow cytometry panel discussed above.

Aim 1 Experiment 3: Determine whether checkpoint blockade induces immunoediting, resulting in increased tumor resistance to immune eradication

In addition to immune suppressive cells, the tumor cells themselves may also undergo immunoediting following checkpoint blockade, to acquire an immune suppressive phenotype. Our goal is to test the hypothesis that tumor cells that evade PD-1 blockade have acquired intrinsic resistance pathways. We used the tumor cells harvested in Aim 1 Experiment 1 subtask 1.3 to address this hypothesis. In the second step, we tested the hypothesis that PD-1 blockade results in a relative increase in the expression of immune suppressive cytokines associated with poor outcomes in ovarian cancer, a phenotype associated with the generation of cancer stem cells (Aim 3), drug and immune resistance in tumor cells (Santisteban et al., 2009; Asiedu et al., 2014; Asiedu et al., 2011).




Figure 9 Assessment of IL-10 cytokine using ELISA: Ascites collected from ID8 and ID8-F3 injected mice were processed and DCs were sorted from the ascites using CD11c magnetic beads. These cells were co-cultured with isotype/ anti-PD1 for 24hrs and the media was collected to measure IL-10 response.

Reportable Outcomes Aim 1 Experiment 3:

In this experiment, we used both ID8 and ID8-F3 model to test whether our hypothesis holds for both cell types. We treated tumor bearing mice (n=5) with α PD-1 and isotype and collected ascites and serum. We sorted Tumor infiltrating dendritic cells from ascites for both treatments and added 200ug of anti-PD1 to these cells in vitro for 24 hours. The DCs from both cell type injections significantly upregulated IL-10. However, there may still be significant differences in cytokine signaling between these two models which will be tested using cytokine blot array. Based on the previous studies published in our lab, we wanted to test the combined effect of anti-PD1 and anti-IL10 neutralizing antibodies to study the tumor burden and survival curve using ID8 as a model.

Specific Aim 2: To determine if co-blockade of IL-10 synergizes with anti-PD-1 to unmask T cell immunity leading to tumor rejection and improved survival

The working hypothesis to be tested in this aim is that checkpoint blockade can be combined with other immune therapies for augmented antitumor efficacy. This premise is based on our preliminary data (unpublished) demonstrating that IL-10 is highly upregulated during treatment with PD-1. IL-10 is one of the most potent immune suppressive cytokines. Thus, it is hypothesized that co-blockade of compensatory immune suppressive networks during treatment with anti-PD-1 may lead to synergistic tumor rejection and possibly long term durable remission.

Aim 2 Experiment 1: To determine the duration of the anti-tumor efficacy of combination PD-1 and IL-10 blockade as well as the potential for durable remissions

We will use the ID8 model in the pilot to evaluate (1) the median improvement in survival in terms of time (weeks or month), (2) tumor burden, and (3) whether tumors that grow out despite demonstrate evidence of immunoediting or if other suppressive networks are activated. Once the tumors are established, mice were treated intraperitoneally with respective antibodies at intervals of 3-5 days.

Experiment 1 Subtask 1: Combination treatment enhances survival of tumor bearing mice




Figure 10 Combination of PD-1 blockade and IL10 neutralization reduces tumor burden and enhances survival of tumor-bearing mice. Left panel shows treatment scheme and right panel shows Kaplan–Meier plot of ID8 tumor–bearing mice (N = 12–16) that were treated intraperitoneally with respective antibodies starting at day 25 post tumor implantation.

Reportable Outcomes Experiment 1 Subtask 1:

In the present work, we identified the TME-associated cytokine IL10 as a critical regulator of the PD-1–PD-L1 axis in the TME. First, we found that IL10, a cytokine whose expression is increased in the TME of several cancers, is capable of increasing PD-1 surface expression in a STAT-3–dependent manner (data not shown). Second, we found that blockade of PD-1, with an antagonistic monoclonal antibody, on DCs led to increased release of IL10 by DC (data shown in Aim 1). Here we show that PD-1 blockade and IL10 signal antagonism as a combination therapy, using blocking antibodies, enhances the antitumor effect in ovarian cancer-bearing mice, leading to significantly improved survival and decrease in tumor burden.

Experiment 1 Subtask 2: Combination treatment reduces the tumor burden

Endpoint determined based on the abdominal distension/ascites volume

Tumor weight = (Tumor disseminated omentum- Age matched healthy omentum)

Tumor measurements at end point




Figure 11 Combination of PD-1 blockade and IL10 neutralization reduces tumor burden and enhances survival of tumor-bearing mice. Mean tumor weights in grams ($\pm$ SEM, N = 5–6), from different treatment groups, as measured at the time of ascites harvest.

Reportable Outcomes Experiment 1 Subtask 2:

IL10 has a major role in evasion of immune-mediated regression of tumor following checkpoint blockade in the present model which is demonstrated by the observation that combination treatment, blockade of PD-1 and IL10(R) significantly reduce the tumor burden. Based on the above data from ID8 model, we plan to extend this study on ID8-F3 cell lines to study immune suppressive networks at different time points using flow cytometry.

Specific Aim 3: To determine if pre-immunization with antigen-specific vaccines augments anti-PD-1 efficacy


PD-1/PD-L1 based blockade therapies inhibit key regulatory loops in the tumor microenvironment leading to clonal expansion of antigen-specific anti-tumor T cells. Tumor eradication is slower than standard chemotherapeutics because T cell immunity activated in response to checkpoint blockade requires clonal expansion, which typically takes weeks to achieve, allowing the tumors sufficient time to evade the immune response. Preliminary data suggests that multi-antigen vaccines targeting malignant epithelial tumor cells, ovarian cancer stem cells, and tumor-associated stroma effectively augment clonal expansion of tumor antigen-specific T cells leading to more complete and durable responses to checkpoint blockade. We proposed that vaccination prior to checkpoint blockade will elevate the levels of anti-tumor T cells to threshold levels required so that clonal expansion outpaces development of compensatory immune suppression, leading to durable regression.

Aim 3 Experiment 1: Determine whether multi-antigen epithelial and stem cell targeting vaccines block ovarian cancer growth

Cancer stem cells (CSCs) have been identified in ovarian cancer tumors, and they are resistant to conventional cancer treatments. Subsequent studies have identified CSCs in solid tumors including OC [8-13]. The current aim was to identify stem cell markers and subsequently select a panel of overexpressed self-antigens which are common in murine and human cell lines.

Subtask 1: Enrich stem cell populations by sphere forming assay to sort for CSCs marker

The tumor spheres express high levels of SC markers and exhibit a great degree of tumorigenicity. Using sphere assays for tumor cells, a number of groups have demonstrated that CSCs efficiently form tumor spheres in a clonogenic manner. These tumor spheres are also chemoresistant and exhibit the upregulation of drug-resistance proteins. For this aim, we investigated 4 cell lines (2 mouse, 2 humans) to characterize cancer stem cell markers and sphere formation. We used ID8 and ID8-F3 cell lines as the murine models and A2780 and SKOV3 as the human counter parts.






B**CSC Surface Markers (SKOV3)****C****SKOV3 summary**


Figure 12 Surface marker analysis and sphere formation assay to identify potential stem cell markers for all the cell lines shown below. A) SKOV3 grown under adherent and non-adherent conditions shows the relative expression of marker candidates for stem cells. B) shows the non-adherent phenotype taken on different days and C) Shows the expression levels of marker candidates for stem cells harvested on different days

A.

CSC Surface Markers (A2780)



B.



C.

A2780 summary




Figure 13 Surface marker analysis and sphere formation assay to identify potential stem cell markers for all the cell lines shown below: A) A2780 grown under adherent and non-adherent conditions shows the relative expression of marker candidates for stem cells. B) Shows the non-adherent phenotype taken on different days and C) Shows the expression levels marker candidates for stem cells harvested on different days.






Figure 14 Surface marker analysis and sphere formation assay to identify potential stem cell markers for all the cell lines shown below: A) ID8 grown under adherent and non-adherent conditions shows the relative expression of marker candidates for stem cells. B) Shows the non- adherent phenotype taken on different days and C) Shows the expression levels marker candidates for stem cells harvested on different days



A.**B.**

Figure 15 Surface marker analysis and sphere formation assay to identify potential stem cell markers for all the cell lines shown below: A) ID8 grown under adherent and non-adherent conditions were compared with the tumors isolated from ascites showing the relative expression of marker candidates for stem cells B) Ascites were cultured on different days in suspension culture and relative expression levels of different candidate markers are shown

Stem cell enrichment using chemotherapy based treatment:

CSCs selected in culture by treatment with paclitaxel to aid in expansion of CSCs in ovarian cancer cell lines. Treatment of cells with 20uM of paclitaxel for 72 hours followed by non-adherent culture conditions demonstrated enrichment of spheroids.

Paclitaxel Treatment

		72 hour harvest			
	Plated	NT- count	NT - viability	Pac+ count	Pac+ viability
ID8	3.00E+05	7.70E+06	96%	4.99E+05	89%
ID8-F3	3.00E+05	7.80E+06	93%	6.60E+05	63%
SKOV3	6.00E+05	1.40E+06	100%	2.99E+05	53%
A2780	3.00E+05	3.80E+06	99%	7.60E+04	65%




Figure 16 Selection of potential Cancer stem cell markers: Four cell lines (A2780, SKOV3, ID8 and ID8-F3) were subjected to paclitaxel treatment for 72 hours and the resulting cells were cultured for additional 3 days in suspension. These cells were then stained for different CSCs markers and compared with non-treated cells in adherent and suspension settings.




Figure 17 Comparison between ID8 and ID8-F3 cancer stem cell markers: These two cell lines were compared in culture condition to evaluate potential stem cell markers in vitro.

Reportable Outcomes Aim 3 Experiment 1:

We have evaluated the stem cell markers for all four cell lines using sphere formation assay and chemotherapy based treatments. There are a number of potential cancer stem cell markers (CD133+, CA125+ and CD326+). We will further investigate the stemness of these cell lines after enriching using bead based sort and culturing these spheroids for a longer period of time. Evidence of stemness will be evaluated using qRTPCR assays looking for stemness associated genes like OCT4, SOX2, Vimentin and Nanog. We further compared mouse cell lines in both adherent and suspension cultures and also with chemo therapy based treatment. We will repeat the experiments to identify candidate stem cell markers and also for statistical significance.

The Key Research Accomplishments:

- Developed flow panels for different immune cell subsets associated with ovarian cancer microenvironment.
- Demonstrated the influence of IL-10 in upregulating the PD-1 expression upon anti-PD1 treatment in tumor bearing mice.
- Demonstrated significant reduction in tumor burden and increased survival in tumor bearing mice upon anti-PD1 and anti-IL-10 combination treatment.
- Identified several ovarian cancer stem cell markers by enriching different ovarian cancer cell lines in suspension culture.

Reportable outcomes:

1. **IL-10 is significantly increased in tumor bearing mice upon anti-PD1 treatment.**
2. **IL-10 plays a vital role in suppressing immune cells in ovarian cancer tumor microenvironment.**
3. **Combination treatment with anti-PD1 and anti-IL-10 in tumor bearing mice significantly reduces tumor burden and improves scope for immunoediting.**

Publications:

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL.

(Under review)

CONCLUSION:

The PD-1/PD-L1 axis is a part of a major immune suppressive network. Blocking this axis leads to enhancement of other immune suppressive mechanism. Our goal is to identify different immune suppressive modulators in ovarian cancer microenvironment. Based on this information we aim to develop strategies to regulate systemic and local immune responses. On the contrary cancer stem cells also play a vital role in tumor recurrence and morbidity. A deeper level of understanding on the mechanism by which the cancer stem cells evades the tumor microenvironment is critical to eradicate ovarian cancer.

REFERENCES:

1. Zhang, L., J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M.N. Liebman, S.C. Rubin, and G. Coukos, *Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer*. N Engl J Med, 2003. **348**(3): p. 203-13 <http://www.ncbi.nlm.nih.gov/pubmed/12529460>.
2. Hamanishi, J., M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, T. Honjo, and S. Fujii, *Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer*. Proc Natl Acad Sci U S A, 2007. **104**(9): p. 3360-5 <http://www.ncbi.nlm.nih.gov/pubmed/17360651>.
3. Josephine Walton, Julianna Blagih, Darren Ennis¹, Elaine Leung, Suzanne Dowson¹, Malcolm Farquharson, Laura A. Tookman, Clare Orange, Dimitris Athineos, Susan Mason, David Stevenson, Karen Blyth, Douglas Strathdee, Frances R. Balkwill, Karen Vousden, Michelle Lockley, and Iain A. McNeish) (CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma DOI: 10.1158/0008-5472.CAN-16-1272 <https://www.ncbi.nlm.nih.gov/pubmed/27530326>
4. Gabrilovich, D.I. and S. Nagaraj, *Myeloid-derived suppressor cells as regulators of the immune system*. Nat Rev Immunol, 2009. **9**(3): p. 162-74 <http://www.ncbi.nlm.nih.gov/pubmed/19197294>.
5. Lan, C., X. Huang, S. Lin, H. Huang, Q. Cai, T. Wan, J. Lu, and J. Liu, *Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer*. Technol Cancer Res Treat, 2013. **12**(3): p. 259-67 <http://www.ncbi.nlm.nih.gov/pubmed/23289476>.
6. Krockenberger, M., Y. Dombrowski, C. Weidler, M. Ossadnik, A. Honig, S. Hausler, H. Voigt, J.C. Becker, L. Leng, A. Steinle, M. Weller, R. Bucala, J. Dietl, and J. Wischhusen, *Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D*. J Immunol, 2008. **180**(11): p. 7338-48 <http://www.ncbi.nlm.nih.gov/pubmed/18490733>.
7. Hamanishi, J., M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, T. Honjo, and S. Fujii, *Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer*. Proc Natl Acad Sci U S A, 2007. **104**(9): p. 3360-5 <http://www.ncbi.nlm.nih.gov/pubmed/17360651>.
8. Nuti, S.V., G. Mor, P. Li, and G. Yin, *TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis*. Oncotarget, 2014. **5**(17): p. 7260-71 <http://www.ncbi.nlm.nih.gov/pubmed/25238494>.
9. Shah, M.M. and C.N. Landen, *Ovarian cancer stem cells: are they real and why are they important?* Gynecol Oncol, 2014. **132**(2): p. 483-9 <http://www.ncbi.nlm.nih.gov/pubmed/24321398>.
10. Yan, H. and Y. Sun, *Evaluation of the mechanism of epithelial-mesenchymal transition in human ovarian cancer stem cells transfected with a WW domain-*

- containing oxidoreductase gene*. *Oncol Lett*, 2014. **8**(1): p. 426-430
<http://www.ncbi.nlm.nih.gov/pubmed/24959289>.
11. Cioffi, M., C. D'Alterio, R. Camerlingo, V. Tirino, C. Consales, A. Riccio, C. Ierano, S.C. Cecere, N.S. Losito, S. Greggi, S. Pignata, G. Pirozzi, and S. Scala, *Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer*. *Sci Rep*, 2015. **5**: p. 10357
<http://www.ncbi.nlm.nih.gov/pubmed/26020117>.
 12. Long, H., T. Xiang, W. Qi, J. Huang, J. Chen, L. He, Z. Liang, B. Guo, Y. Li, R. Xie, and B. Zhu, *CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition*. *Oncotarget*, 2015. **6**(8): p. 5846-59
<http://www.ncbi.nlm.nih.gov/pubmed/25788271>.
 13. Wang, X., X. Li, X. Fu, M. Bai, Q. Mei, J. Nie, Z. Wu, and W. Han, *Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance*. *Curr Protein Pept Sci*, 2015. **16**(4): p. 270-8
<http://www.ncbi.nlm.nih.gov/pubmed/25929861>.
 14. Zhang G, L Ma, YK Xie, XB Miao and C Jin. (2012). Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity. *Mol Med Report* 6:519–524.
 15. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. *J Immunol*. 2011 Jun 15;186(12):6905-13. doi:10.4049/jimmunol.1100274. Epub 2011 May 6. <https://www.ncbi.nlm.nih.gov/pubmed/21551365>